WebLog Journal of Internal Medicine

Review Article
Published: 15 Aug, 2026

Minocycline: A Comprehensive Review of Its Antibiotic and Pleiotropic Actions, Pharmacokinetics, and Therapeutic Landscape

Bhumika Saini*

Saraswathi College of Pharmacy (SCOP), Anwarpur, Pilkhuwa, Hapur District, Uttar Pradesh, India

Abstract

Minocycline, a semi-synthetic, second-generation tetracycline antibiotic, has long been a cornerstone in the treatment of various infectious diseases and, notably, acne vulgaris [1, 2]. Its primary mechanism of action involves binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis [3]. However, contemporary research has revealed that Minocycline possesses significant pleiotropic effects that extend far beyond its antimicrobial properties, including potent anti-inflammatory, immunomodulatory, and neuroprotective actions [4, 5]. These non-antibiotic properties are attributed to its high lipophilicity, which grants it superior tissue penetration, particularly across the blood-brain barrier, distinguishing it from first-generation tetracyclines [4]. This review synthesizes the current understanding of Minocycline's dual mechanism of action, its favorable pharmacokinetic profile, its established and emerging therapeutic applications, and its associated safety and adverse effect profile, highlighting its unique and evolving role in modern medicine.

Keywords: Minocycline; Tertacycline; Pleiotropic Actions; Pharmacokinetics; Neuroprotective; Anti-inflammatory; Matrix Metalloproteinases (MMP); Microglial Activarion; Acne Vulgaris; Blood Brain Barrier (BBB); Lipophilicity; Antibiotic Resistance

Correspondence:
Bhumika Saini, Saraswathi College of Pharmacy (SCOP), Anwarpur, Pilkhuwa, Hapur District, Uttar Pradesh, India, Tel: +91 6397142040; E-mail: bhumikasaini1011@gmail.com

Received Date: *02 Jul 2026*
Accepted Date: *13 Aug 2026*
Published Date: *15 Aug 2026*

Citation:
Bhumika Saini. Minocycline: A Comprehensive Review of Its Antibiotic and Pleiotropic Actions, Pharmacokinetics, and Therapeutic Landscape. WebLog J Intern Med. wjim.2026.h1503. https://doi.org/10.5281/zenodo.22172797

Introduction

The tetracycline class: A historical perspective

The tetracyclines are a class of broad-spectrum antibiotics that have been in clinical use since the late 1940s [3]. The first member, chlortetracycline, was discovered in 1945 as a natural product of *Streptomyces aureofaciens*. These compounds are characterized by a common hydronaphthacene skeleton containing four fused rings. While the first-generation tetracyclines (e.g., tetracycline, oxytetracycline) were revolutionary, they were limited by poor oral bioavailability and frequent dosing requirements [1].

Development and evolution of minocycline

Minocycline was developed in the 1960s and approved for medical use in 1971 [1]. As a second-generation tetracycline, it was designed to overcome the limitations of its predecessors. By modifying the tetracycline core - specifically adding a dimethylamino group at the 7-position - scientists created a molecule with significantly higher lipophilicity [4]. This structural change not only improved its antibacterial potency but also fundamentally altered its pharmacokinetic behavior, allowing it to penetrate biological membranes and reach privileged sites like the Central Nervous System (CNS) more effectively than any other tetracycline [4].

The paradigm shift: From antibiotic to pleiotropic agent

For decades, Minocycline was viewed strictly through the lens of infectious disease. However, the late 1990s and early 2000s marked a paradigm shift [4]. Researchers discovered that Minocycline could inhibit Matrix Metalloproteinases (MMPs) and modulate immune responses in ways that were entirely independent of its ability to kill bacteria [5]. This discovery opened the door to investigating Minocycline in a vast array of conditions, from rheumatoid arthritis to neurodegenerative diseases like Parkinson's and Multiple Sclerosis [6].

Scope and objectives of this review

This article provides an exhaustive analysis of Minocycline. It delves into the molecular mechanisms underlying both its antimicrobial and pleiotropic actions, examines its unique pharmacokinetic and metabolic pathways, and provides a critical evaluation of its clinical utility across multiple medical specialties [4]. Furthermore, it addresses the complex safety profile of the drug, including rare but serious adverse events that clinicians must navigate [2, 7].

Chemical Structure and Properties

Molecular architecture

Minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline) is a semi-synthetic derivative [1]. Its chemical formula is $C_{23}H_{27}N_3O_7$. The core structure consists of four fused rings (A, B, C, and D). The addition of the dimethylamino group at the C7 position of the D ring is the defining feature that confers its high lipid solubility [4].

Physicochemical characteristics

• Lipophilicity: Minocycline is the most lipid-soluble of all commercially available tetracyclines [4]. This property allows it to pass easily through the lipid bilayers of bacterial cell walls and human cell membranes, including the Blood-Brain Barrier (BBB) and the blood-cerebrospinal fluid barrier [6].

• Chelation: Like other tetracyclines, Minocycline is a potent chelator of divalent and trivalent metal ions (e.g., Ca^{2+}, Mg^{2+}, Al^{3+}, Fe^{3+}) [3]. This chelation is central to its mechanism of action (binding to the ribosome) but also underlies its interactions with food and certain medications [8].

• Stability: It is relatively stable in acidic environments, contributing to its high oral bioavailability [1].

Mechanism of Action

Minocycline's therapeutic efficacy is bipartite, involving a well-defined antibacterial mechanism and a complex, multi-faceted set of non-antibiotic (pleiotropic) actions [4].

Antibacterial mechanism: Inhibition of protein synthesis

Minocycline is a bacteriostatic antibiotic [3]. Its primary target is the bacterial ribosome (Table 1).

1. Active Transport: Minocycline enters susceptible Gram-negative bacteria through porin channels (OmpF and OmpC) *via* passive diffusion and is then actively transported across the inner cytoplasmic membrane [9]. In Gram-positive bacteria, the process is primarily energy-dependent active transport.

2. Ribosomal Binding: Once inside the cell, Minocycline binds reversibly to the 30S subunit of the bacterial ribosome, specifically at the H34 site within the 16S rRNA [3].

3. Inhibition of Translation: This binding sterically blocks the docking of aminoacyl-tRNA to the A-site (acceptor site) of the mRNA-ribosome complex [3]. Consequently, new amino acids cannot be added to the nascent peptide chain, halting protein synthesis and preventing bacterial growth and replication [1].

Table 1:

Mechanism	Description
Target	Binds reversibly to the **30S ribosomal subunit** of susceptible bacteria [3].
Action	Blocks the binding of aminoacyl-tRNA to the acceptor site (A-site) on the mRNA-ribosome complex [2].
Result	Prevents the addition of new amino acids to the growing peptide chain, leading to inhibition of protein synthesis and bacteriostatic activity [3].

Spectrum of Activity: Minocycline exhibits broad-spectrum activity against a wide range of organisms [1]:

• Gram-positive: *Staphylococcus aureus* (including some MRSA strains), *Streptococcus pneumoniae.*

• Gram-negative: *Neisseria meningitidis*, *Haemophilus influenzae*, and various Enterobacteriaceae.

• Atypical Pathogens: *Chlamydia trachomatis*, *Mycoplasma pneumoniae*, and Rickettsia species.

Non-Antibiotic (pleiotropic) mechanisms

The pleiotropic effects of Minocycline are mediated through several distinct molecular pathways, making it a potent modulator of inflammation and cell death [4, 6].

Inhibition of Matrix Metalloproteinases (MMPs): MMPs are calcium-dependent, zinc-containing endopeptidases involved in the degradation of extracellular matrix components [4]. Overexpression of MMPs (especially MMP-2 and MMP-9) is linked to tissue destruction in rheumatoid arthritis, periodontitis, and the breakdown of the blood-brain barrier in stroke and MS [4, 6]. Minocycline inhibits MMPs by:

• Directly chelating the zinc ion at the enzyme's active site [4].

• Downregulating the expression of MMP genes at the transcriptional level [4].

Modulation of microglial activation: In the CNS, microglia are the primary immune effectors [10]. Chronic or excessive microglial activation leads to the release of neurotoxic factors [11]. Minocycline is a potent inhibitor of microglial activation [10]. It shifts microglia from a pro-inflammatory (M1) phenotype to an anti-inflammatory/repair (M2) phenotype, thereby reducing the production of:

• Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) [4].

• Reactive Oxygen Species (ROS) [4].

• Nitric oxide (*via* inhibition of inducible Nitric Oxide Synthase, iNOS) [4].

Anti-Apoptotic pathways; Minocycline exerts neuroprotective effects by interfering with programmed cell death (apoptosis) [6]:

• Mitochondrial Stabilization: It prevents the opening of the mitochondrial Permeability Transition Pore (mPTP) [6].

• Inhibition of Cytochrome c Release: By stabilizing the mitochondrial membrane, it prevents the leakage of cytochrome c into the cytosol, a key step in the intrinsic apoptotic pathway [6].

• Caspase Inhibition: It has been shown to downregulate the activation of Caspase-1 and Caspase-3 [6].

• PARP-1 Inhibition: Minocycline inhibits Poly(ADP-ribose) polymerase-1, an enzyme that, when overactivated by DNA damage, leads to cellular energy depletion and death (parthanatos) [6].

Inhibition of signaling pathways: Minocycline interferes with several intracellular signaling cascades involved in inflammation [12], including:

• NF-κB Pathway: It inhibits the translocation of Nuclear Factor-kappa B to the nucleus, preventing the transcription of multiple inflammatory genes [12].

• MAPK Pathways: It suppresses the activation of p38 Mitogen-

Activated Protein Kinase (MAPK) and c-Jun N-terminal Kinase (JNK), which are critical for stress responses and cytokine production [12].

Pharmacokinetics and Metabolism

Minocycline's pharmacokinetic profile is superior to most other tetracyclines, characterized by high bioavailability and extensive tissue distribution [4].

Absorption

• Bioavailability: Following oral administration, Minocycline is rapidly and almost completely absorbed (90-100%) [1].

• Food Effect: Unlike first-generation tetracyclines, the absorption of Minocycline is not significantly affected by the presence of food or dairy products [1]. However, it should still not be taken simultaneously with antacids containing aluminum, calcium, or magnesium, as these can form non-absorbable chelates [8].

• Peak Plasma Concentration (Cmax): Typically reached within 1 to 4 hours (Tmax) [1].

Distribution

• Lipophilicity and Tissue Penetration: Due to its high lipid solubility, Minocycline has a large volume of distribution [4]. It penetrates effectively into:

1. CNS: Achieves 20-25% of serum concentrations in the CSF and even higher levels in brain parenchyma [4].

2. Skin and Sebum: Concentrates in the pilosebaceous unit, which is critical for its efficacy in acne [2].

3. Other: Saliva, tears, prostate, and lungs [1].

• Protein Binding: Approximately 70-80% of Minocycline is bound to plasma proteins (primarily albumin) [1].

Metabolism

Minocycline is unique among tetracyclines in that it undergoes significant hepatic metabolism [1].

• Metabolic Pathways: Approximately 50% of the dose is metabolized in the liver [1].

• Primary Metabolites: The major metabolite is 9-hydroxyminocycline. Other metabolites include N-demethylated derivatives [1]. These metabolites generally possess less antimicrobial activity than the parent compound.

Excretion

• Biliary Excretion: The primary route of elimination is through the bile and feces (approximately 20-34%) [1].

• Renal Excretion: Only a small fraction (4-19%) is excreted unchanged in the urine [1].

• Half-life: Minocycline has a long elimination half-life, ranging from 11 to 22 hours in healthy individuals [1]. This allows for convenient once- or twice-daily dosing [1].

• Renal Impairment: Because it is not primarily cleared by the kidneys, Minocycline does not accumulate significantly in patients with renal failure, and dose adjustments are typically not required [1].

Table 2:

Feature	Tetracycline	Doxycycline	Minocycline
Generation	First	Second	Second
Lipophilicity	Low	High	Very High
Absorption	60-80%	90-100%	90-100%
Food Interference	Significant	Minimal	Negligible
Half-life	6-8 hours	15-25 hours	11-22 hours
CNS Penetration	Poor	Moderate	Excellent
Primary Excretion	Renal	Biliary/Fecal	Biliary/Fecal
Vestibular Toxicity	Rare	Rare	Common
Hyperpigmentation	Rare	Rare	Common

Comparative Analysis: Minocycline *vs.* Other Tetracyclines

To understand Minocycline's unique clinical value, it is essential to compare it with its closest relatives, Tetracycline (1st generation) and Doxycycline (2nd generation) (Table 2) [1, 4].

Advantages of minocycline

The primary advantage of Minocycline over Doxycycline is its superior tissue penetration, particularly into the brain and prostate [4]. Additionally, its nearly complete absorption regardless of food intake makes it more convenient for patients [1].

Disadvantages

The main drawbacks are the higher incidence of vestibular side effects (dizziness) and the risk of long-term hyperpigmentation, which are less common with Doxycycline [2, 7].

Mechanisms of Bacterial Resistance

As with all antibiotics, the emergence of resistance is a significant concern [9]. Bacteria have developed several strategies to evade the action of Minocycline.

Efflux pumps

This is the most common mechanism [9]. Bacteria (e.g., *E. coli*, *S. aureus*) express membrane-bound transport proteins (such as the Tet(A) and Tet(B) pumps) that actively pump the antibiotic out of the cell before it can reach the ribosome [9]. Interestingly, Minocycline is sometimes effective against bacteria that are resistant to tetracycline because it is a poor substrate for certain efflux pumps [9].

Ribosomal Protection Proteins (RPPs)

Proteins such as Tet(M) and Tet(O) bind to the ribosome and induce a conformational change that dislodges the tetracycline molecule or prevents it from binding, even in the presence of high intracellular drug concentrations [9].

Enzymatic inactivation

Though less common, some bacteria produce enzymes (e.g., Tet(X)) that chemically modify and inactivate the tetracycline molecule through oxidation [9].

Therapeutic Applications in Dermatology

Acne vulgaris

Minocycline is a first-line systemic treatment for moderate-to-severe inflammatory acne [2]. Its efficacy is dual-pronged:

1. Antibacterial: It reduces the population of *Cutibacterium acnes*

(formerly *Propionibacterium acnes*) within the follicles [2].

2. Anti-inflammatory: It inhibits neutrophil chemotaxis and reduces the production of free fatty acids in sebum, which are potent triggers for inflammation [2].

Rosacea

While doxycycline is often preferred for rosacea, Minocycline is an effective alternative, particularly for the papulopustular subtype [2]. It works by modulating the innate immune response and inhibiting the inflammatory cascade associated with the disease [2].

Bullous disorders

Minocycline, often in combination with nicotinamide, is used as a steroid-sparing agent in the treatment of Bullous Pemphigoid [2]. Its ability to inhibit MMP-9 and neutrophil recruitment helps prevent the subepidermal blistering characteristic of the disease [2].

Pyoderma Gangrenosum and Sarcoidosis

Due to its potent anti-inflammatory effects, Minocycline is used off-label for neutrophilic dermatoses like Pyoderma Gangrenosum and cutaneous sarcoidosis, where it helps stabilize the immune response and reduce tissue destruction [2].

Applications in Dentistry and Ophthalmology

Periodontitis

Minocycline is used in dentistry both systemically and topically (e.g., microspheres) [13].

• MMP Inhibition: In periodontitis, the destruction of the periodontal ligament and alveolar bone is largely mediated by host MMPs [13]. Minocycline inhibits these enzymes, slowing the progression of the disease [13].

• Sub-antimicrobial Dosing: Similar to doxycycline, low-dose minocycline can be used for its anti-collagenase effects without exerting selective pressure for antibiotic resistance [13].

Meibomian Gland Dysfunction (MGD) and Rosacea Blepharitis

In ophthalmology, Minocycline is used to treat chronic eyelid inflammation [14].

• Mechanism: It reduces the production of bacterial lipases that break down meibomian lipids into irritating free fatty acids [14].

• Clinical Benefit: It improves the stability of the tear film and reduces the symptoms of dry eye associated with MGD [14].

Neurological and Psychiatric Applications (Investigational)

The neuroprotective and anti-inflammatory properties of Minocycline have led to its investigation in a wide range of CNS disorders [6,15].

Multiple Sclerosis (MS)

In MS, the breakdown of the BBB and the infiltration of T-cells and macrophages lead to demyelination [15]. Minocycline's ability to inhibit MMPs (which degrade the BBB) and modulate microglial activation has shown promise [15].

• Clinical Evidence: Phase II and III trials have suggested that Minocycline can reduce the risk of conversion from a Clinically Isolated Syndrome (CIS) to definite MS and may reduce the number of gadolinium-enhancing lesions on MRI [15, 16].

Parkinson's Disease (PD)

In PD, neuroinflammation and microglial activation contribute to the loss of dopaminergic neurons in the substantia nigra [15].

• Preclinical Studies: Minocycline has shown robust neuroprotection in MPTP models of Parkinson's [6].

• Clinical Status: Human trials have yielded mixed results, with some large-scale studies failing to show a significant slowing of disease progression, highlighting the difficulty of translating animal model success to human neurodegeneration [15].

Stroke and Traumatic Brain Injury (TBI)

Following an ischemic stroke or TBI, a secondary wave of inflammation causes further neuronal damage [6]. Minocycline has been investigated for its ability to:

• Reduce infarct size [6].

• Protect the integrity of the BBB [6].

• Inhibit the post-ischemic inflammatory response [6].

Psychiatric disorders

Emerging evidence suggests that "neuroinflammation" plays a role in the pathophysiology of several psychiatric conditions [17].

• Schizophrenia: Minocycline has been studied as an adjunct to antipsychotics [17]. Meta-analyses suggest it may be particularly effective in improving "negative symptoms" (e.g., social withdrawal, lack of motivation) and cognitive deficits [17].

• Major Depressive Disorder (MDD): Due to its anti-inflammatory effects, Minocycline is being explored as an add-on therapy for patients with treatment-resistant depression who show elevated markers of systemic inflammation (e.g., high C-reactive protein) [17].

• Fragile X Syndrome and Autism: Preliminary studies have suggested that Minocycline might improve behavioral symptoms by modulating synaptic plasticity and microglial function [17].

Cardiovascular and Oncological Research (Emerging)

Cardioprotection

Recent studies have explored Minocycline's role in protecting the heart from ischemia-reperfusion injury [18].

• Mechanism: By inhibiting PARP-1 and reducing oxidative stress, Minocycline can limit the size of myocardial infarctions in animal models [18].

• Clinical Potential: It is being investigated as a potential adjunct therapy during reperfusion procedures (like angioplasty) to minimize secondary cardiac damage [18].

Oncology and metastasis

While not a primary chemotherapy agent, Minocycline's inhibition of MMPs has implications for cancer research [19].

• Anti-Angiogenesis: By inhibiting MMP-2 and MMP-9, Minocycline may interfere with the ability of tumors to form new blood vessels and invade surrounding tissues [19].

• Metastasis: Some preclinical models suggest that Minocycline can reduce the metastatic potential of certain cancers, such as glioma and breast cancer, by modulating the tumor microenvironment [19].

Safety and Adverse Effects

While Minocycline is generally well-tolerated, its unique chemical properties lead to a specific profile of adverse effects that differ from other tetracyclines [1, 2].

Common and vestibular side effects

• Gastrointestinal: Nausea and vomiting are common [7]. CDAD (Clostridioides Difficile-Associated Diarrhea) is a risk, as with all broad-spectrum antibiotics [20].

• Vestibular Toxicity: Dizziness, vertigo, and ataxia occur in up to 30-50% of patients, more frequently in women [21]. This is due to the drug's high lipophilicity, allowing it to concentrate in the vestibular fluid of the inner ear [21].

Hyperpigmentation

Minocycline is notorious for causing tissue discoloration, which can be categorized into three types [22]:

• Type I: Blue-black discoloration in areas of previous inflammation or scarring (e.g., acne scars) [22].

• Type II: Blue-gray pigmentation on normal skin, most commonly on the shins and forearms [22].

• Type III: Generalized "muddy" brown discoloration, often in sun-exposed areas [22].

• Other Sites: Discoloration can also affect the teeth (even in adults), nails, sclera, and even internal organs (e.g., "black thyroid") [7].

Autoimmune reactions

Minocycline is associated with rare but serious idiosyncratic autoimmune syndromes [7]:

• Drug-Induced Lupus Erythematosus (DILE): Characterized by arthralgia, fever, and positive Antinuclear Antibodies (ANA) [7]. It typically occurs after long-term use (months to years) [7].

• Autoimmune Hepatitis: Can present as jaundice and elevated liver enzymes [7].

• DRESS Syndrome: Drug Reaction with Eosinophilia and Systemic Symptoms is a life-threatening hypersensitivity reaction involving rash, fever, and organ failure [7].

Benign intracranial hypertension (Pseudotumor cerebri)

Minocycline can cause an idiopathic increase in intracranial pressure [7]. Symptoms include severe headache, nausea, and papilledema (swelling of the optic disc), which can lead to permanent vision loss if not recognized and treated by discontinuing the drug [7].

Drug Interactions and Contraindications

Key interactions

• Multivalent Cations: Antacids, iron supplements, and calcium-rich foods can significantly reduce absorption [8].

• Retinoids: Concurrent use with oral isotretinoin increases the risk of pseudotumor cerebri and should be avoided [8].

• Anticoagulants: Tetracyclines can enhance the effect of warfarin by interfering with Vitamin K production by gut bacteria [8].

• Oral Contraceptives: There is a theoretical risk of reduced efficacy, though clinical evidence for this is weak [8].

Contraindications

• Pregnancy and Lactation: Classified as Category D [8]. It crosses the placenta and can cause permanent tooth discoloration and inhibition of bone growth in the fetus [8].

• Pediatrics: Generally avoided in children under 8 years of age for the same reasons [8].

• Hypersensitivity: Known allergy to any tetracycline [8].

Future Perspectives: Non-Antibiotic Analogs

A major concern with using Minocycline for chronic non-infectious conditions is the risk of promoting antibiotic resistance in the global microbiome [23]. To address this, researchers are developing SARM (Specially Altered Resolution Modulators) or non-antimicrobial tetracycline analogs (e.g., 10-butyl ether minocycline) [23]. These molecules retain the anti-inflammatory and neuroprotective properties but lack the ability to bind to the bacterial ribosome, potentially allowing for long-term use without the risk of resistance [23].

Conclusion

Minocycline is a remarkable example of pharmacological versatility [4]. From its origins as a potent second-generation antibiotic to its current status as a promising candidate for treating complex neurological and psychiatric disorders, it continues to challenge our understanding of drug action [15]. Its superior pharmacokinetics and ability to cross the blood-brain barrier make it uniquely suited for CNS applications [4]. However, its use requires a careful balancing act, weighing its significant therapeutic benefits against the risks of vestibular toxicity, hyperpigmentation, and rare autoimmune reactions [2, 7]. As research into non-antimicrobial analogs progresses, the legacy of Minocycline may well transition from the treatment of infection to the management of chronic inflammation and neurodegeneration [23].

Acknowledgements

“I would like to express my sincere gratitude to my guide, Dr. Nidhi Tyagi and my co-guide Dr. Nitin Kumar, for their invaluable guidance, constant encouragement, and expert supervision throughout the preparation of this review. I am also deeply thankful to Saraswathi College of Pharmacy (SCOP) for providing the necessary resources and a conducive environment for my research. Their support has been instrumental in the successful completion if this work.

References

1. Nazarian S, Akhondi H. Minocycline. StatPearls. 2023.
2. Baldwin H. A Review of Systemic Minocycline Side Effects and Topical Minocycline. Antibiotics. 2021.
3. DrugBank Online. Minocycline: Uses, Interactions, Mechanism of Action.
4. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013; 169(2): 337-3352.
5. Garrido-Mesa N, Zarzuelo A, Gálvez J. What is behind the non-antibiotic properties of minocycline? Pharmacol Res. 2013; 67(1): 18-30.
6. Noble W, Garwood CJ, Hanger DP. Minocycline as a potential therapeutic

agent in neurodegenerative disorders. Prion. 2009; 3(2): 78-83.

7. Minocycline Capsules & Tablets: Uses & Side Effects. Cleveland Clinic.
8. Minocycline (oral route) - Side effects & dosage. Mayo Clinic.
9. Chopra I, Roberts M. Minocycline, focus on mechanisms of resistance. Drug Resistance Updates. 2020.
10. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001; 21(8): 2580-2588.
11. Cheng S, Hou J, Zhang C, Xu C, Wang L, Zou X, et al. Minocycline reduces neuroinflammation but does not ameliorate neuron loss in a mouse model of neurodegeneration. Sci Rep. 2015; 5: 10535.
12. Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics. Curr Mol Pharmacol. 2021; 14(6): 1046-1065.
13. Pihlstrom BL. Minocycline-HCl microspheres for the treatment of periodontitis. Journal of Periodontology. 2003.
14. Blackie CA. Minocycline and meibomian gland dysfunction. Clinical & Experimental Ophthalmology. 2011.
15. Romero-Miguel D, Lamanna-Rama N, Casquero-Veiga M, Gómez-Rangel V, Desco M, Soto-Montenegro ML. Minocycline in neurodegenerative and psychiatric diseases: an update. Eur J Neurol. 2021; 28(3): 1056-1081.
16. Metz LM. Minocycline in multiple sclerosis: a phase 3 trial. New England Journal of Medicine. 2017.
17. Panizzutti B, Skvarc D, Lin S, Croce S, Meehan A, Bortolasci CC, et al. Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis. Int J Mol Sci. 2023; 24(6): 5250.
18. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. Cardiac Uptake of Minocycline and Mechanisms for In Vivo Cardioprotection. J Am Coll Cardiol. 2008; 52(13): 1086-1094.
19. Lala PK. Minocycline and doxycycline: a review of their anti-cancer properties. Cancer Metastasis Reviews. 2014.
20. Minocycline Side Effects: Common, Severe, Long Term. Drugs.com.
21. 9 Oral Minocycline Side Effects and How to Manage Them. GoodRx. 2023.
22. Smith K. Minocycline-induced hyperpigmentation: a review. Journal of Clinical and Aesthetic Dermatology. 2015.
23. Shaik AA, Panthagani P, Liu X, Navarro-Turk S, Garza J, Aguilera M, et al. Molecular mechanisms of 10-Butyl Ether Minocycline (BEM), a novel non-antibiotic tetracycline, as a potential treatment for inflammatory and neuroimmune-related disorders. 2025.
24. Yun HM, Noh S, Hyun S. Minocycline treatment suppresses juvenile development and growth by attenuating insulin/TOR signaling in Drosophila animal model. Nature. 2017.
25. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Am J Physiol. 2010; 299(3): C539-C548.